Characteristic
|
CHC (n = 34)
|
SHC (n = 29)
|
Pure HCC (n = 50)
|
Pure ICC (n = 50)
|
P valuec
|
---|
|
V1
|
V2
|
V3
|
---|
Sex
|
Men
|
30 (88.2)
|
25 (86.2)
|
47 (94.0)
|
35 (70.0)
|
0.810
|
0.383
|
0.051
|
Women
|
4 (11.8)
|
4 (13.8)
|
3 (6.0)
|
15 (30.0)
|
Age (years)a
|
52 (24–78)
|
49 (24–81)
|
53 (26–73)
|
60 (42–81)
|
0.434
|
0.713
|
0.342
|
Tumor size (cm)b
|
4.05 ± 2.45
|
3.49 ± 2.11▲
|
6.26 ± 2.81
|
5.24 ± 3.42
|
0.237▲
|
0.146
| |
|
2.96 ± 1.68▼
| | |
0.168▼
| |
0.293
|
HBsAg (+)
|
32 (94.1)
|
27 (93.1)
|
43 (86.0)
|
28 (56.0)
|
1.000
|
0.301
|
<0.001
|
Liver cirrhosis
|
20 (58.9)
|
12 (41.4)
|
34 (86.0)
|
12 (24.0)
|
0.167
|
0.389
|
<0.001
|
Vascular invasion
|
17 (50.0)
|
9 (31.0)
|
1 (2.0)
|
6 (12.0)
|
0.128
|
<0.001
|
<0.001
|
Lymph node metastasis
|
6 (17.6)
|
4 (13.8)
|
0 (0.0)
|
10 (20.0)
|
0.741
|
0.003
|
0.787
|
AFP ≥20 μg/L
|
24 (70.6)
|
20 (69.0)
|
33 (66.0)
|
15 (30.0)
|
0.889
|
0.659
|
<0.001
|
CA19–9 ≥38 U/mL
|
14 (41.2)
|
27 (93.1)
|
2 (2.0)
|
22 (44.0)
|
<0.001
|
<0.001
|
0.797
|
AFP ≥20 μg/L and CA19–9 ≥38 U/mL
|
10 (29.4)
|
4 (13.8)
|
1 (2.0)
|
5 (10.0)
|
0.137
|
<0.001
|
0.023
|
HCC
|
Histologic type
|
Coarse trabecular pattern
|
21 (61.8)
|
19 (65.5)
|
34 (68.0)
| |
0.025
|
0.834
| |
Fine trabecular pattern
|
3 (8.8)
|
8 (27.6)
|
4 (8.0)
| | | | |
Others
|
10 (29.4)
|
2 (6.9)
|
12 (24.0)
| | | | |
Edmondson grade
|
I–II
|
4 (11.8)
|
11 (37.9)
|
9 (18.0)
| |
0.015
|
0.438
| |
III–IV
|
30 (88.2)
|
18 (62.1)
|
41 (82.0)
| | | | |
ICC
|
Histologic type
|
Tubular pattern
|
29 (85.3)
|
28 (96.6)
| |
46 (92.0)
|
0.139
| |
0.266
|
Others
|
5 (14.7)
|
1 (3.4)
| |
4 (8.0)
| | | |
Differentiation grade
|
Moderate and well
|
24 (70.6)
|
25 (86.2)
| |
29 (58.0)
|
0.137
| |
0.241
|
Poor
|
10 (29.4)
|
4 (13.8)
| |
21 (42.0)
| | | |
Overall survival time (months)b
|
15.37 ± 2.04
|
24 ± 4.23
|
29.2 ± 4.1
|
10.1 ± 2.3
|
0.047
|
0.021
|
0.017
|
Disease-free survival time (months)b
|
8.85 ± 1.3
|
16.9 ± 3.6
|
22.7 ± 3.9
|
5.62 ± 0.7
|
0.038
|
<0.001
|
0.397
|
-
CHC combined hepatocellular and cholangiocarcinoma, SHC separated hepatocellular carcinoma and intrahepatic cholangiocarcinoma, HCC hepatocellular carcinoma, ICC intrahepatic cholangiocarcinoma, HBsAg 15 hepatitis B surface antigen, AFP ɑ-fetoprotein, CA19-9 carbohydrate antigen 19-9, ▲ HCC, ▼ ICC
-
aThese values are presented as median followed by range in the parentheses
-
bThese data are presented as mean ±standard deviation; other values are presented as number of patients followed by percentage in the parentheses
-
c
P value for V1 CHC versus SHC; V2 CHC versus pure HCC; V3 CHC versus pure ICC